The overall goal of this PPG is to understand the genetic, genomic, and epigenetic determinants of variable susceptibility to develop COPD. Three COPD susceptibility loci have recently been definitively identified by genome-wide association studies???two loci on chromosome 4 (near HHIP and in FAM13A) and one locus on chromosome 15 (a block of genes including IREB2). However, the key genetic determinants in these regions and their functional impact on COPD have not been defined. The three projects In this PPG focus on Genetics (Project 1, PI: Silverman);Gene Expression (Project 2, PI: Choi);and DNA Methylation (Project 3, PI: DeMeo). These projects will build on a substantial existing infrastructure of well-phenotyped study populations, experience in phenotypic characterization of COPD, and an extensive track record of both in vitro and in vivo functional assessment of COPD pathogenesis. There are likely multiple additional COPD susceptibility loci, which need to be discovered. Some of these genetic loci may be influenced primarily by epigenetic alterations (e.g. DNA methylation) instead of, or In addition to, heritable SNP variation. Moreover, the other gene members of the pathways related to these genetic determinants of COPD are unknown, and assessment of gene expression and DNA methylation can likely provide insight into these pathways. Thus, we have included Discovery of additional gene expression and epigenetic influences on COPD susceptibility as a central focus of this PPG. In addition, the actual genetic determinants within the GWAS loci have not been proven. Thus, we have included efforts to localize the key genes within those regions. Multiple approaches will be used to accomplish this goal. Including assessment of genetic association in a population of different genetic ancestry (African Americans from the COPDGene project), analysis of gene expression among genes within GWAS loci, assessment for epigenetic changes of genes within GWAS loci, and assays of long-range gene regulation (e.g. chromosome conformation capture). In addition to Localization of the key determinants, Functional Validation will be required to confirm that specific genes are Involved in COPD pathogenesis and to understand their impact. We will employ both in vitro assessment within lung epithelial and monocyte cell lines (with validation in primary cell types) as well as in vivo assessment in murine models of underexpression (knockout) of the key genes and susceptible vs. resistant Inbred strains which are tested with long-term cigarette smoke exposure. We anticipate that these studies will provide insight into the pathways and mechanisms for COPD susceptibility.

Public Health Relevance

COPD is a major public health problem. Although It Is exciting to finally have genetic loci that almost certainly contribute to COPD susceptibility, the identification of these loci is just the beginning of a long path that could lead to improved understanding of COPD pathogenesis and, ultimately, to improved COPD treatment. This proposal will develop new insights into COPD genetics, genomics, and epigenetics, which will provide major progress toward this reality.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL105339-03
Application #
8501655
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Program Officer
Postow, Lisa
Project Start
2011-08-17
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
3
Fiscal Year
2013
Total Cost
$2,324,962
Indirect Cost
$799,002
Name
Brigham and Women's Hospital
Department
Type
DUNS #
030811269
City
Boston
State
MA
Country
United States
Zip Code
02115
Busch, Robert; Qiu, Weiliang; Lasky-Su, Jessica et al. (2016) Differential DNA methylation marks and gene comethylation of COPD in African-Americans with COPD exacerbations. Respir Res 17:143
Putman, Rachel K; Hatabu, Hiroto; Araki, Tetsuro et al. (2016) Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA 315:672-81
Hardin, M; Cho, M H; McDonald, M-L et al. (2016) A genome-wide analysis of the response to inhaled β2-agonists in chronic obstructive pulmonary disease. Pharmacogenomics J 16:326-35
Cloonan, Suzanne M; Choi, Augustine M K (2016) Mitochondria in lung disease. J Clin Invest 126:809-20
Lao, Taotao; Jiang, Zhiqiang; Yun, Jeong et al. (2016) Hhip haploinsufficiency sensitizes mice to age-related emphysema. Proc Natl Acad Sci U S A 113:E4681-7
Jiang, Zhiqiang; Lao, Taotao; Qiu, Weiliang et al. (2016) A Chronic Obstructive Pulmonary Disease Susceptibility Gene, FAM13A, Regulates Protein Stability of β-Catenin. Am J Respir Crit Care Med 194:185-97
Hardin, Megan; Foreman, Marilyn; Dransfield, Mark T et al. (2016) Sex-specific features of emphysema among current and former smokers with COPD. Eur Respir J 47:104-12
Chang, Yale; Glass, Kimberly; Liu, Yang-Yu et al. (2016) COPD subtypes identified by network-based clustering of blood gene expression. Genomics 107:51-8
Busch, Robert; Han, MeiLan K; Bowler, Russell P et al. (2016) Risk factors for COPD exacerbations in inhaled medication users: the COPDGene study biannual longitudinal follow-up prospective cohort. BMC Pulm Med 16:28
Wang, Longfei; Lee, Sungyoung; Gim, Jungsoo et al. (2016) Family-Based Rare Variant Association Analysis: A Fast and Efficient Method of Multivariate Phenotype Association Analysis. Genet Epidemiol 40:502-11

Showing the most recent 10 out of 85 publications